Glucose-induced loss of glycosyl-phosphatidylinositol-anchored membrane regulators of complement activation (CD59, CD55) by in vitro cultured human umbilical vein endothelial cells.
OBJECTIVE
This study examines whether increased glucose concentrations are responsible for a decreased expression of membrane regulators of complement activation molecules. The effect of high glucose in determining an increase in membrane attack complex deposition on endothelial cells was also investigated.


METHODS
Endothelial cells were isolated from umbilical cord tissue, cultured in the presence of increased concentrations of glucose, and the expression of CD46, CD55, and CD59 was detected by ELISA (enzyme-linked immunosorbent assay) and by flow cytometry. Glucose-treated endothelial cells were also incubated with antiendothelial cell antibodies and fresh complement to assess the amount of membrane attack complex formation.


RESULTS
High concentrations of glucose decreased the expression of CD59 and CD55 by endothelial cells in a time-dependent and glucose concentration-dependent manner without affecting CD46 expression. High concentrations of soluble CD59 were found in the supernatants of cells treated with high glucose. The decrease in CD59 expression induced by high glucose concentrations was reversed by coincubation of cells with a calcium channel blocking agent (Verapamil). All of these effects were not reproduced by osmotic control media. Cells treated with concentrations of high glucose were more susceptible to complement activation and membrane attack complex formation after exposure to antiendothelial cell antibodies.


CONCLUSIONS
We speculate that hyperglycaemia could directly contribute to a loss of CD59 and CD55 molecules through a calcium-dependent phosphoinositol-specific phospholipase C activation and subsequent regulation of cell wall expression of GPI-anchored proteins. This phenomenon could facilitate the activation of a complement pathway and could play a part in the aetiology of endothelial dysfunction in diabetes.
Accardo-Palumbo
A
A
Department of Internal Medicine, University of Palermo, Italy.
Triolo
G
G
Colonna-Romano
G
G
Potestio
M
M
Carbone
M
M
Ferrante
A
A
Giardina
E
E
Caimi
G
G
Triolo
G
G
D015703:Antigens, CD / Q000187:drug effects / Q000502:physiology; D018958:CD55 Antigens / Q000187:drug effects / Q000502:physiology*; D018957:CD59 Antigens / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D003167:Complement Activation / Q000502:physiology; D015938:Complement Membrane Attack Complex / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005947:Glucose / Q000494:pharmacology*; D017261:Glycosylphosphatidylinositols / Q000378:metabolism*; D006801:Humans; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy; D014471:Umbilical Veins
D015703:Antigens, CD; C497857:CD46 protein, human; D018958:CD55 Antigens; D018957:CD59 Antigens; D015938:Complement Membrane Attack Complex; D017261:Glycosylphosphatidylinositols; D051916:Membrane Cofactor Protein; D008562:Membrane Glycoproteins; D005947:Glucose